Corticosteroid therapy

Phase 3Small molecule

Sanofi

Corticosteroid therapy is one of 45 small molecule programs targeting Granuloma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GranulomaActive, not recruiting

AsthmaActive, not recruiting

GranulomaPreclinical

Active, not recruiting

AsthmaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Cinqair

Teva

Preclinical

13 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 5

Corticosteroid therapy

Sanofi

Phase 3

1 6

Celexa

AbbVie

Preclinical

1 7

Atrovent

Boehringer Ingelheim

Preclinical

5 8

Arcoxia

Symbicort

6 10

Aciphex

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Not yet recruiting

Non-Segmental Vitiligo

NCT07673640

Clinical

Trials by Indication[1]

Asthma1 trial

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Completed· Sanofi logo

Sanofi·Phase 3·NCT02528214·210 enrolled

Granuloma1 trial

Ductal Lavage Versus Corticosteroids Therapy for Idiopathic Granulomatous Mastitis

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT03724903·140 enrolled

Non-segmental Vitiligo1 trial

Efficacy and Safety of Ruxolitinib Phosphate Cream Combined With Corticosteroids in Patients With Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

Not yet recruiting·SShanShan Li··NCT07673640·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Corticosteroid therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Corticosteroid therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Corticosteroid therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Corticosteroid therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Asthma1 trial

Granuloma1 trial

Non-segmental Vitiligo1 trial

References

Drug Info

Quick Facts

Related News